<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517892</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01147-40</org_study_id>
    <secondary_id>2014/2144</secondary_id>
    <nct_id>NCT02517892</nct_id>
  </id_info>
  <brief_title>A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents</brief_title>
  <acronym>MATCH-R</acronym>
  <official_title>A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study to identify molecular mechanisms of acquired resistance to&#xD;
      targeted therapies in patients with unresectable or metastatic cancer.&#xD;
&#xD;
      This is a protocol to study clinical characteristics and biopsy tissue of patients with&#xD;
      oncogene-driven cancer who have had previous clinical response to targeted therapy and&#xD;
      subsequently experience progression of disease. The tissues and other specimens will be used&#xD;
      to carry out laboratory studies to explore the molecular basis of acquired resistance to&#xD;
      targeted therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type and frequency of molecular alterations in resistant tumors using whole exome sequencing</measure>
    <time_frame>30 days after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Metastatic Oncogen-driven Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with metastatic oncogen-driven cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <arm_group_label>Patients with metastatic oncogen-driven cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients diagnosed with confirmed cancer and who fulfill the following eligibility criteria&#xD;
        will be considered eligible for this study:&#xD;
&#xD;
          1. Patient affiliated to a social security regimen&#xD;
&#xD;
          2. Patients scheduled to receive anticancer agents or currently receiving anticancer&#xD;
             agents&#xD;
&#xD;
          3. Tumor lesion accessible to core biopsies (malignant effusions can represent an&#xD;
             alternative)&#xD;
&#xD;
          4. Patient who is fully informed, able to comply with the protocol and who signed the&#xD;
             informed consent.&#xD;
&#xD;
          5. Availability of initial tumor material (ideally frozen, or non-Bouin fixed paraffin&#xD;
             embedded material) acquired before exposure to the targeted therapy Note: Patients may&#xD;
             have received other treatments since treatment with targeted therapies including&#xD;
             radiation or chemotherapy, before undergoing the study biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Coagulation abnormality prohibiting a biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine ITALIANO, MD-PhD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>antoine.italiano@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie Abou Lovergne</last_name>
    <phone>0142113862</phone>
    <phone_ext>+33</phone_ext>
    <email>aurélie.aboulovergne@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Charles Soria, MD-PhD</last_name>
      <phone>0142114391</phone>
      <phone_ext>+33</phone_ext>
      <email>soria@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aurélie Abou Lovergne</last_name>
      <phone>0142113862</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelie.aboulovergne@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

